THE PROTAC DT2216 TARGETS CANCER BY PROMOTING BCL-XL DEGRADATION

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2020年 / 10卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [1] Degradation of Bcl-xL by DT2216 is lethal to T-cell acute lymphoblastic leukemia.
    Jaiswal, Arunima S.
    Williamson, Elizabeth
    Hromas, Robert A.
    Zhou, Daohong
    CANCER RESEARCH, 2022, 82 (12)
  • [2] BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
    Khan, Sajid
    Wiegand, Janet
    Zhang, Peiyi
    Hu, Wanyi
    Thummuri, Dinesh
    Budamagunta, Vivekananda
    Hua, Nan
    Jin, Lingtao
    Allegra, Carmen J.
    Kopetz, Scott E.
    Zajac-Kaye, Maria
    Kaye, Frederic J.
    Zheng, Guangrong
    Zhou, Daohong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [3] BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
    Sajid Khan
    Janet Wiegand
    Peiyi Zhang
    Wanyi Hu
    Dinesh Thummuri
    Vivekananda Budamagunta
    Nan Hua
    Lingtao Jin
    Carmen J. Allegra
    Scott E. Kopetz
    Maria Zajac-Kaye
    Frederic J. Kaye
    Guangrong Zheng
    Daohong Zhou
    Journal of Hematology & Oncology, 15
  • [4] Targeting Bcl-XL in Anaplastic Large Cell Lymphoma Using the Synthetic Proteolytic DT2216
    Medina, Edward
    Zhou, Daohong
    Zheng, Guangrong
    Hromas, Robert
    Kinney, Marsha
    Esparza, Javier
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1349 - 1349
  • [5] Targeting Bcl-XL in Anaplastic Large Cell Lymphoma Using the Synthetic Proteolytic DT2216
    Medina, Edward
    Zhou, Daohong
    Zheng, Guangrong
    Hromas, Robert
    Kinney, Marsha
    Esparza, Javier
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1349 - 1349
  • [6] Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models
    Zhang, Qi
    Khan, Sajid
    Zhang, Xuan
    Kuruvilla, Vinitha Mary
    Ghotbaldini, Sanaz
    Wells, Julia
    Baran, Natalia
    Cai, Tianyu
    Han, Lina
    Ferrando, Adolfo
    Kim, Yong-Mi
    Zheng, Guangrong
    Zhou, Daohong
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [7] Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis
    Jaiswal, Arunima
    Jaiswal, Aruna
    Williamson, Elizabeth A.
    Gelfond, Jonathon
    Zheng, Guangrong
    Zhou, Daohong
    Hromas, Robert
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (01) : 89 - 95
  • [8] Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis
    Arunima Jaiswal
    Aruna Jaiswal
    Elizabeth A. Williamson
    Jonathon Gelfond
    Guangrong Zheng
    Daohong Zhou
    Robert Hromas
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 89 - 95
  • [9] DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia
    He, Yonghan
    Koch, Raphael
    Budamagunta, Vivekananda
    Lv, Dongwen
    Khan, Sajid
    Zhang, Xuan
    Wiegand, Janet S.
    Zheng, Guangrong
    Weinstock, David M.
    Zhou, Daohong
    BLOOD, 2019, 134
  • [10] Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
    Wang, Zhe
    Skwarska, Anna
    Poigailwar, Gowri
    Chaudhry, Sovira
    Rodriguez-Meira, Alba
    Sui, Pinpin
    Olivier, Emmanuel
    Jia, Yannan
    Ramage, Cassandra L.
    Zheng, Guangrong
    Schurer, Alexandra
    Gritsman, Kira
    Papapetrou, Eirini
    Bhalla, Kapil N.
    Zhou, Daohong
    Mead, Adam J.
    Rampal, Raajit
    Tyner, Jeffrey W.
    Abbas, Hussein A.
    Pemmaraju, Naveen
    Tatarata, Qi Zhang
    Konopleva, Marina
    BLOOD, 2024, 144 : 2749 - 2751
12345